View Future GrowthInteger Holdings 過去の業績過去 基準チェック /56Integer Holdingsは、平均年間7.8%の収益成長を遂げていますが、 Medical Equipment業界の収益は、年間 成長しています。収益は、平均年間13.6% 11.2%収益成長率で 成長しています。 Integer Holdingsの自己資本利益率は8.4%であり、純利益率は7.6%です。主要情報7.83%収益成長率6.74%EPS成長率Medical Equipment 業界の成長8.90%収益成長率11.16%株主資本利益率8.36%ネット・マージン7.64%前回の決算情報03 Apr 2026最近の業績更新Reported Earnings • May 01First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: EPS: US$0.48 (up from US$0.66 loss in 1Q 2025). Revenue: US$439.6m (flat on 1Q 2025). Net income: US$16.5m (up US$39.0m from 1Q 2025). Profit margin: 3.8% (up from net loss in 1Q 2025). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 02Integer Holdings Corporation to Report Q1, 2026 Results on Apr 30, 2026Integer Holdings Corporation announced that they will report Q1, 2026 results Pre-Market on Apr 30, 2026Reported Earnings • Feb 20Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: US$2.96 (down from US$3.60 in FY 2024). Revenue: US$1.85b (up 8.0% from FY 2024). Net income: US$102.8m (down 15% from FY 2024). Profit margin: 5.5% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.3%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 22Integer Holdings Corporation to Report Q4, 2025 Results on Feb 19, 2026Integer Holdings Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 19, 2026分析記事 • Nov 05Some May Be Optimistic About Integer Holdings' (NYSE:ITGR) EarningsThe most recent earnings report from Integer Holdings Corporation ( NYSE:ITGR ) was disappointing for shareholders...Reported Earnings • Oct 24Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$1.13 (up from US$1.08 in 3Q 2024). Revenue: US$467.7m (up 8.4% from 3Q 2024). Net income: US$39.7m (up 9.4% from 3Q 2024). Profit margin: 8.5% (up from 8.4% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.0%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.すべての更新を表示Recent updatesSeeking Alpha • May 21Integer Holdings: Rare Public Asset Soon To Be SoldSummary Integer Holdings Corp. is a unique, high-quality medical device CDMO trading at a depressed ~10x EBITDA multiple after a temporary growth slowdown. A strategic review, prompted by activist involvement and heightened buyer interest, positions ITGR for a likely sale within three to four months. Precedent CDMO transactions support a fair value of $110–125/share (13–14x forward EBITDA), offering 20–40% upside with limited downside risk. ITGR’s entrenched OEM relationships, high switching costs, and diversified pipeline underpin its competitive moat and long-term growth prospects. Read the full article on Seeking Alphaライブニュース • May 15Integer Holdings Jumps Over 5% on Analyst Upgrade and Potential Sale ReviewInteger Holdings stock moved more than 5% higher after an Oppenheimer analyst upgraded the rating to buy. The upgrade was based on an ongoing review that could result in a potential sale of the company. The analyst highlighted Integer’s position as a contract developer and manufacturer of medical devices as a key reason it may appeal to private equity buyers. The focus on a potential sale puts extra attention on Integer’s business profile and profitability, as those factors often matter to financial buyers looking at specialized healthcare suppliers. Investors should keep in mind that interest from potential acquirers does not guarantee any transaction or specific terms, and deal speculation can add volatility to the stock.ナラティブの更新 • May 07ITGR: Fair View Sees 2026 Product Drag Easing As Portfolio Review ProgressesInteger Holdings' analyst fair value estimate has increased from $93.25 to $95.00 as analysts factor in updated price targets from Citi, BofA, and Raymond James, along with more cautious assumptions for growth, margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the stock as recent price targets such as US$101 indicate confidence in the company’s ability to support a higher valuation over time.お知らせ • May 03Integer Holdings Corporation Announces Earnings Guidance for the Year 2026Integer Holdings Corporation announced earnings guidance for the year 2026. For the year, the company expects as reported sales in the range of $1,805 million to $1,835 million decrease of 3% to 1% as compared to previous year, operating income in the range of $165 million to $185 million decrease of 25% to 16% as compared to previous year, net income in the range of $105 million to $125 million increase of 2% to 21% as compared to previous year, and diluted earnings per share in the range of $3.07 to $3.64 increase of 6% to 26% as compared to previous year.Reported Earnings • May 01First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: EPS: US$0.48 (up from US$0.66 loss in 1Q 2025). Revenue: US$439.6m (flat on 1Q 2025). Net income: US$16.5m (up US$39.0m from 1Q 2025). Profit margin: 3.8% (up from net loss in 1Q 2025). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.ナラティブの更新 • Apr 20ITGR: Fair View Expects 2026 Product Drag To Fade As Pipeline BuildsAnalysts have lifted their price targets on Integer Holdings to a range of about $92 to $101, reflecting updated views on the timing of headwinds from underperforming products and the potential contribution from new products after 2026. Analyst Commentary Recent price target revisions cluster in a range of about $92 to $101, which signals that analysts see room for upside but also recognize execution questions around product transitions and growth consistency.お知らせ • Apr 08Integer Holdings Corporation, Annual General Meeting, May 20, 2026Integer Holdings Corporation, Annual General Meeting, May 20, 2026. Location: hilton dallas/plano granite park hotel, 5805 granite parkway, plano, plano United Statesお知らせ • Apr 07Integer Holdings Corporation Announces Pamela G. Bailey, Independent Chair of the Board Will Not Stand for Re-Election At 2026 AGMInteger Holdings Corporation announced Pamela G. Bailey, who currently serves as Integer’s independent Chair of the Board, will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026.ナラティブの更新 • Apr 05ITGR: Fair View Sees 2026 Headwinds Easing As Newer Products Gain TractionAnalysts have raised Integer Holdings' implied price target range to about $92 to $101. This reflects updated views that near term product headwinds could ease by 2026, supported by contributions from newer products.お知らせ • Apr 02Integer Holdings Corporation to Report Q1, 2026 Results on Apr 30, 2026Integer Holdings Corporation announced that they will report Q1, 2026 results Pre-Market on Apr 30, 2026ナラティブの更新 • Mar 20ITGR: Fair View Sees 2026 Product Headwinds Easing As Recovery ProgressesAnalysts have nudged their price expectations for Integer Holdings higher, with the updated fair value moving from $92.63 to $93.25 as they factor in recent target increases and ongoing work to address product headwinds and potential future growth drivers. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price targets, now clustered in the low to low triple digits, as recognition that recent headwinds are already reflected in expectations and that current valuation assumes a measured recovery path.お知らせ • Mar 12Integer Holdings Corporation Announces Board Changes, Effective March 12, 2026Integer Holdings Corporation has appointed two new directors to its Board of Directors: James F. Flanagan and Aaron Kapito. These appointments are effective as of March 12, 2026, and the board size has been increased to 13 members. The Cooperation Agreement also stipulates that two incumbent directors will not stand for re-election at the 2026 Annual Meeting of Stockholders. The agreement includes provisions for the appointment of the new directors to specific board committees, including the Audit Committee, the Compensation and Organization Committee, and the Technology Strategy Committee. The Cooperation Agreement includes voting commitments, standstill restrictions, and mutual non-disparagement provisions, which remain in place until the earlier of 30 days prior to the advance notice deadline for the 2027 Annual Meeting or one year from the effective date of the agreement. Mr. Flanagan is the former Chief Operating Officer of PwC from 2014 to 2021, bringing proven diversified, strategic, operational and qualified financial expertise through 39 years of increasing client and management roles. Previously, he also served as PwC’s US Financial Services Practice Leader from 2006 to 2014, and prior to that as the Transaction Services Leader from 2001 to 2006 and Transaction Services Partner from 1994 to 2001. He has served on the Board of Directors at Belami Ecommerce, a subsidiary of SkyX Platforms Corp. from 2022 to 2025, while also serving as Audit Committee Chair. Mr. Flanagan received a B.S. in Accounting from the C.W. Post School of Professional Accountancy at Long Island University. Mr. Kapito is a Partner at Politan Capital Management L.P., an investment management firm that he co-founded in 2021. Previously, Mr. Kapito served as a Senior Analyst at Lion Point Capital from 2018 to 2021, a Senior Analyst and founding member of Delonix Capital from 2016 to 2017, and an Associate Portfolio Manager for Elliott Management L.P. from 2011 to 2016. Mr. Kapito currently serves on the boards of Rocky Mountain Steel Mills, a manufacturer of high-performance steel products, and Associated Veterinary Partners, a veterinary clinic platform. Mr. Kapito received a B.S. in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.ナラティブの更新 • Mar 06ITGR: Fair View Balances 2026 Product Headwinds And New Launch RecoveryNarrative Update Analysts have lifted their blended price target on Integer Holdings to $92.63 from $85.57, citing updated views on future P/E, revenue growth headwinds tied to a few underperforming products and an eventual recovery supported by new product contributions. Analyst Commentary Recent research has focused on how Integer balances valuation against execution risks tied to specific product headwinds and future growth ambitions.Recent Insider Transactions Derivative • Mar 03CEO, President & Director exercised options and sold US$1.5m worth of stockOn the 24th of February, Payman Khales exercised options to acquire 17k shares at no cost and sold these for an average price of US$87.10 per share. This trade did not impact their existing holding. For the year to December 2019, Payman's total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Payman's direct individual holding has increased from 19.74k shares to 25.47k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months.New Risk • Feb 22New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 42% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results.Price Target Changed • Feb 22Price target increased by 7.4% to US$91.88Up from US$85.57, the current price target is an average from 8 analysts. New target price is 8.3% above last closing price of US$84.85. Stock is down 35% over the past year. The company is forecast to post earnings per share of US$4.19 for next year compared to US$2.96 last year.Reported Earnings • Feb 20Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: US$2.96 (down from US$3.60 in FY 2024). Revenue: US$1.85b (up 8.0% from FY 2024). Net income: US$102.8m (down 15% from FY 2024). Profit margin: 5.5% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.3%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.ナラティブの更新 • Feb 19ITGR: Fair Value Holds As FY26 Reacceleration Faces Confidence RebuildAnalysts have trimmed their price target on Integer Holdings to $86 from $88, citing expectations that it may take a few quarters before investors gain confidence in a potential reacceleration discussed for the second half of FY26. Analyst Commentary Recent research reflects a slightly more cautious stance on Integer Holdings, with the price target adjusted to $86 from $88.お知らせ • Feb 19Integer Holdings Corporation Provides Earnings Guidance for the Year 2026Integer Holdings Corporation provided earnings guidance for the year 2026. For the year, the company expects as reported sales in the range of $1,826 million to $1,876 million, operating income in the range of $184 million to $204 million, net income in the range of $121 million to $138 million, and diluted earnings per share in the range of $3.53 to $4.01.ナラティブの更新 • Feb 05ITGR: Fair Value Holds As 2026 Reacceleration Awaits Coatings Asset IntegrationAnalysts reduced their price target for Integer Holdings to US$86 from US$88, citing expectations that it may take a few quarters before investors are comfortable underwriting a potential re acceleration in the second half of FY26. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares, suggesting they still see support for the current valuation even with a slightly lower price target.お知らせ • Jan 28Integer Holdings Corporation to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During Md&M West 2026Integer Holdings Corporation will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 - 5. Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company's full range of customer solutions. On prominent display will be R&D Velocity, Integer's integrated R&D ecosystem connecting design, prototyping and manufacturing to help medical device companies develop products that are manufacturable from the start, accelerating the time between design and manufacturability. The company will showcase several solutions - delivered through a network of locations globally - that are central to R&D Velocity, including: Differentiated Technology Platforms: Proven product technologies that enable, accelerate and de-risk the development of customers' next generation devices. Global Capabilities and Expertise: Specialized labs and integrated manufacturing all in one ecosystem along with dedicated engineers and global centers of excellence to accelerate every phase of development. Ease of Manufacturability: Designs optimized early to scale seamlessly, reducing rework and accelerating launch. Rapid Prototyping: Engineer-to-engineer collaboration delivering prototypes in as little as two weeks. Integer will additionally highlight a range of key product areas and innovations during MD&M West, including: Integer Medical Coatings: The company continues to expand its role as a fully integrated coating partner for medical devices, strengthening its ability to deliver end-to-end surface-modification solutions. Integer will also showcase its full coatings portfolio, including PTFE, PTFE alternatives, hydrophilic coatings, parylene, and advanced surface-modification technologies. Following the acquisitions of Precision Coating,VSi Parylene, and certain Biocoat assets last year, Integer has further strengthened its position as a fully integrated coating partner For medical devices. Cardiac Rhythm Management and Neuromodulation: Miniaturized technologies for finished IPG systems, as well as Gen 3 Li-Ion and Gen 2 CFx batteries. Cardio and Vascular: A full range of electrophysiology, structural heart, and neurovascular product solutions including complex catheters, guidewires, steerable introducers and sheaths, therapy delivery systems and implant technologies.お知らせ • Jan 22Integer Holdings Corporation to Report Q4, 2025 Results on Feb 19, 2026Integer Holdings Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 19, 2026ナラティブの更新 • Jan 21ITGR: Fair Value Suggests Recovery As 2026 Demand Visibility Gradually ImprovesAnalysts have modestly trimmed their blended price target for Integer Holdings to about $86, down from prior targets clustered closer to $88 and above. This reflects caution around the company's softer 2026 outlook and reduced visibility on the timing of any potential demand recovery.ナラティブの更新 • Jan 07ITGR: Fair Value Suggests Shares Will Recover As 2026 Visibility ImprovesAnalysts have inched their fair value estimate for Integer Holdings higher to about US$85.57 from roughly US$84.29, reflecting lower assumed discount rates and a slightly higher future P/E multiple. This follows recent research updates that cut price targets and ratings but still highlight the potential for recovery once revenue visibility improves.ナラティブの更新 • Dec 17ITGR: Shares Will Recover As 2026 Demand Visibility And Orders Gradually StabilizeThe analyst price target for Integer Holdings has been trimmed modestly, with analysts citing reduced 2026 visibility, order and demand headwinds across several newer product launches, and a longer wait for growth reacceleration as reasons for resetting expectations, even as they see the recent share price pullback as overdone. Analyst Commentary Bullish analysts acknowledge the near term reset to expectations but argue that the recent compression in Integer Holdings valuation already discounts a prolonged period of slower growth and execution risk.お知らせ • Dec 11Saxena White P.A. Files Securities Fraud Class Action Against Integer Holdings Corporation and Certain of its ExecutivesSaxena White P.A. has filed a securities fraud class action lawsuit (the “Class Action”) in the United States District Court for the Southern District of New York against Integer Holdings Corporation (“Integer” or the “Company”) and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder on behalf of all persons or entities that purchased Integer common stock between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Saxena White is captioned West Palm Beach Firefighters’ Pension Fund v. Integer Holdings Corporation, et al., No. 25-cv-10251 (S.D.N.Y.).Based in Plano, Texas, Integer purports to be one of the medical device contract development and manufacturing organizations in the world. The Company contracts with medical device companies to manufacture cardiac rhythm management and cardio and vascular (“C&V”) medical devices. Integer’s C&V product line generates approximately 60% of the Company’s total revenue. As a part of the C&V product line, Integer manufactures electrophysiology (“EP”) devices, which diagnose and map the heart’s electrical activity to address problems such as irregular heartbeats (cardiac arrhythmias).Prior to the Class Period, EP devices underwent a technological revolution as Integer customers began to develop devices for pulse field ablation (“PFA”) procedures that use brief, high-energy electrical pulses to treat atrial fibrillation. In turn, the industry became increasingly focused on integrating EP devices and PFA platforms to effectuate a more seamless cardiac procedure. As a result, EP devices represented a significant growth driver for Integer’s C&V segment. Leading up to the Class Period, CEO Dziedzic described PFA platforms as “a tailwind” due to the Company’s “vertically integrated offering[,]” while also touting that Integer “benefit[ed] significantly from electrophysiology procedure growth.” CEO Dziedzic further explained, “We participate in the full procedure, which is one of the strengths of Integer.” The Class Action alleges that, during the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose that: (1) Integer materially overstated its competitive position within the growing EP manufacturing market; (2) despite Integer’s claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company’s C&V segment; (4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.ナラティブの更新 • Dec 03ITGR: Shares Will Recover As 2026 Demand Visibility Gradually ImprovesAnalysts have trimmed their price target on Integer Holdings slightly, to about $84.57 from roughly $84.86, as they factor in softer near term visibility and delayed confidence in a second half 2026 re acceleration, despite longer term optimism about the company’s recovery and customer relationships. Analyst Commentary Street research following Integer Holdings recent update reflects a sharply reset near term outlook, but also a degree of longer term confidence in the company’s strategic positioning and customer relationships.ナラティブの更新 • Nov 19ITGR: Shares Will Recover As Order Headwinds Are ResolvedInteger Holdings' average analyst price target has sharply decreased, dropping from above $120 to a range of $77 to $88. Analysts cite concerns that recent order shifts, lowered guidance, and uncertainty in the 2026 outlook justify a reset in valuation expectations for the stock.分析記事 • Nov 06What You Can Learn From Integer Holdings Corporation's (NYSE:ITGR) P/E After Its 35% Share Price CrashInteger Holdings Corporation ( NYSE:ITGR ) shareholders that were waiting for something to happen have been dealt a...分析記事 • Nov 05Some May Be Optimistic About Integer Holdings' (NYSE:ITGR) EarningsThe most recent earnings report from Integer Holdings Corporation ( NYSE:ITGR ) was disappointing for shareholders...お知らせ • Nov 05Integer Holdings Corporation (NYSE:ITGR) announces an Equity Buyback for $200 million worth of its shares.Integer Holdings Corporation (NYSE:ITGR) announces a share repurchase program. Under the program, the company will repurchase up to $200 million worth of its common stock. The company intends to primarily utilize cash on hand and free cash flows to fund the share repurchase program. The program has no expiration date.ナラティブの更新 • Nov 05ITGR: Shares Will Recover As Demand Normalizes And Inventory Pressures EaseInteger Holdings’ analyst price target has been revised significantly lower, dropping from approximately $137 to $85 per share. Analysts cite headwinds from reduced revenue growth expectations and a weaker 2026 outlook following order changes to three key products.Buy Or Sell Opportunity • Oct 30Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 41% to US$63.32. The fair value is estimated to be US$80.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 5.6% in 2 years. Earnings are forecast to grow by 106% in the next 2 years.Reported Earnings • Oct 24Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$1.13 (up from US$1.08 in 3Q 2024). Revenue: US$467.7m (up 8.4% from 3Q 2024). Net income: US$39.7m (up 9.4% from 3Q 2024). Profit margin: 8.5% (up from 8.4% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.0%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Price Target Changed • Oct 24Price target decreased by 38% to US$86.00Down from US$139, the current price target is an average from 7 analysts. New target price is 18% above last closing price of US$72.91. Stock is down 42% over the past year. The company is forecast to post earnings per share of US$2.80 for next year compared to US$3.60 last year.お知らせ • Oct 24+ 1 more updateInteger Holdings Corporation Announces CEO Changes, Effective October 24, 2025Integer Holdings Corporation appointed Payman Khales as Chief Executive Officer, effective October 24, 2025. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business, where he led a successful market- and customer-focused strategy, doubling sales in seven years and driving above-market growth, while further improving service levels and profitability. Most recently, as Chief Operating Officer, he oversaw both of Integer's business units and its global operations, further strengthening Integer's reputation as a strategic partner to medical device companies and OEMs worldwide. Prior to joining Integer, Mr. Khales held senior leadership roles at CECO Environmental Corp. and Ingersoll Rand Company. He holds an Executive MBA from Indiana University's Kelley School of Business and a Bachelor of Science in Mechanical Engineering from cole Polytechnique de Montréal. As previously disclosed, also effective October 24, 2025, Mr. Dziedzic will serve as a Special Advisor for the Company until March 31, 2026, to assist Mr. Khales with transition matters.お知らせ • Oct 23+ 1 more updateInteger Holdings Corporation Provides Earnings Guidance for the Year 2026 and Year 2027Integer Holdings Corporation provided earnings guidance for the year 2026 and year 2027. For the year 2026, the company expects Reported sales to be down 2% to up 2% and Organic sales to be flat to up 4%. For the year 2027, the company expects growth 200 basis points above market.ナラティブの更新 • Oct 22Analysts Lower Integer Holdings Price Target Amid Cautious Sector Outlook and Stable Growth ProjectionsAnalysts have lowered their price target for Integer Holdings from $137.00 to $121.00, citing market volatility concerns and a cautious outlook for new investment within the MedTech sector, even as expectations remain for healthy quarterly performance. Analyst Commentary Recent analyst notes provide a balanced view of Integer Holdings, with both optimism and caution expressed regarding the company’s outlook and sector dynamics.お知らせ • Sep 25Integer Holdings Corporation to Report Q3, 2025 Results on Oct 23, 2025Integer Holdings Corporation announced that they will report Q3, 2025 results Pre-Market on Oct 23, 2025分析記事 • Sep 09Is It Too Late To Consider Buying Integer Holdings Corporation (NYSE:ITGR)?While Integer Holdings Corporation ( NYSE:ITGR ) might not have the largest market cap around , it received a lot of...分析記事 • Aug 12What You Can Learn From Integer Holdings Corporation's (NYSE:ITGR) P/EWith a price-to-earnings (or "P/E") ratio of 44.1x Integer Holdings Corporation ( NYSE:ITGR ) may be sending very...分析記事 • Jul 22We Think Integer Holdings (NYSE:ITGR) Can Stay On Top Of Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jul 11Integer Holdings Corporation Appoints Michael Coyle to Board of DirectorsInteger Holdings Corporation announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies. Before that, he was executive vice president and group president of Medtronic’s cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career. Coyle is currently a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies Inc. and Volcano Corporation. He earned a master's degree in business administration from the Wharton School of Business, University of Pennsylvania, and a bachelor's degree from Case Western Reserve University. He additionally holds six U.S. patents related to cardiovascular medical device products and technologies.分析記事 • Jul 08Integer Holdings Corporation (NYSE:ITGR) Shares Could Be 30% Below Their Intrinsic Value EstimateKey Insights Integer Holdings' estimated fair value is US$167 based on 2 Stage Free Cash Flow to Equity Integer...お知らせ • Jun 30+ 5 more updatesInteger Holdings Corporation(NYSE:ITGR) dropped from Russell 3000 Value IndexInteger Holdings Corporation(NYSE:ITGR) dropped from Russell 3000 Value Indexお知らせ • Jun 26Integer Holdings Corporation to Report Q2, 2025 Results on Jul 24, 2025Integer Holdings Corporation announced that they will report Q2, 2025 results at 8:00 AM, US Eastern Standard Time on Jul 24, 2025分析記事 • Jun 25Returns On Capital At Integer Holdings (NYSE:ITGR) Have StalledTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...Recent Insider Transactions Derivative • Jun 05Independent Director notifies of intention to sell stockDonald Spence intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of June. If the sale is conducted around the recent share price of US$120, it would amount to US$1.8m. Since March 2025, Donald has owned 18.78k shares directly. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months.Buy Or Sell Opportunity • May 28Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 3.6% to US$119. The fair value is estimated to be US$151, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 166% in the next 2 years.分析記事 • May 25Is Now The Time To Look At Buying Integer Holdings Corporation (NYSE:ITGR)?Integer Holdings Corporation ( NYSE:ITGR ), might not be a large cap stock, but it saw a double-digit share price rise...分析記事 • May 02Some May Be Optimistic About Integer Holdings' (NYSE:ITGR) EarningsShareholders appeared unconcerned with Integer Holdings Corporation's ( NYSE:ITGR ) lackluster earnings report last...Buy Or Sell Opportunity • Apr 30Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to US$126. The fair value is estimated to be US$158, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 166% in the next 2 years.New Risk • Apr 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 36% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results.Reported Earnings • Apr 25First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2025 results: US$0.66 loss per share (down from US$0.61 profit in 1Q 2024). Revenue: US$437.4m (up 5.4% from 1Q 2024). Net loss: US$22.5m (down 210% from profit in 1Q 2024). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year.お知らせ • Apr 25Integer Holdings Corporation Provides Earnings Guidance for the Year 2025Integer Holdings Corporation provided earnings guidance for the year 2025. For the year, the company expects sales in the range of $1,846 million to $1,880 million, Operating income in the range of $242 million to $258 million, Income from continuing operations of $108 million to $120 million, Diluted earnings per share in the range of $3.00 to $3.36.お知らせ • Apr 24+ 1 more updateInteger Holdings Corporation Announces CEO Changes, Effective October 24, 2025Integer Holdings Corporation announced that Joseph Dziedzic will retire as Chief Executive Officer, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the CEO position. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026. Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business. Under his leadership, the business established a successful market/customer-based strategy, doubling sales in seven years, accelerating market penetration, and achieving above-market growth, while improving service levels and profitability. Since becoming COO, he has overseen both of Integer’s business units, Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation, along with global operations and manufacturing strategy. Mr. Khales currently serves as COO of Integer, and previously served as President of the Cardio & Vascular product category since 2018. Prior to joining Integer, Mr. Khales served as President of the Environmental Technologies business segment for CECO Environmental Corp., a diversified global provider of engineered technologies to the environmental, energy, and fluid handling and filtration industrial segments. He also held several progressive leadership roles at Ingersoll Rand Company. Mr. Khales holds an Executive Master of Business Administration from Indiana University’s Kelley School of Business, and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal.分析記事 • Apr 15These 4 Measures Indicate That Integer Holdings (NYSE:ITGR) Is Using Debt Reasonably WellLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Buy Or Sell Opportunity • Apr 08Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to US$107. The fair value is estimated to be US$138, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 6.7% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.分析記事 • Apr 03Estimating The Intrinsic Value Of Integer Holdings Corporation (NYSE:ITGR)Key Insights Using the 2 Stage Free Cash Flow to Equity, Integer Holdings fair value estimate is US$143 Integer...お知らせ • Mar 27Integer Holdings Corporation to Report Q1, 2025 Results on Apr 24, 2025Integer Holdings Corporation announced that they will report Q1, 2025 results at 8:00 AM, Eastern Standard Time on Apr 24, 2025分析記事 • Mar 20Integer Holdings (NYSE:ITGR) Hasn't Managed To Accelerate Its ReturnsIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...お知らせ • Mar 19Integer Holdings Corporation, Annual General Meeting, May 21, 2025Integer Holdings Corporation, Annual General Meeting, May 21, 2025. Location: 5830 granite parkway, suite 1150, plano, texas 75024, United StatesRecent Insider Transactions Derivative • Mar 14President exercised options and sold US$1.6m worth of stockOn the 11th of March, Joseph Dziedzic exercised options to acquire 13k shares at no cost and sold these for an average price of US$120 per share. This trade did not impact their existing holding. For the year to December 2018, Joseph's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Joseph's direct individual holding has increased from 222.32k shares to 291.78k. Company insiders have collectively sold US$9.7m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Feb 21+ 1 more updateInteger Holdings Corporation (NYSE:ITGR) signed a purchase agreement to acquire Vertical Solutions, Inc for $28 million.Integer Holdings Corporation (NYSE:ITGR) signed a purchase agreement to acquire Vertical Solutions, Inc. for $28 million on February 18, 2025. The consideration is payable $23 million in cash and $5 million in Integer common stock, subject to customary purchase price adjustments, offset by an expected $3 million NPV tax benefit. The expected completion of the transaction is by the end of February 2025.Reported Earnings • Feb 20Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: US$3.60 (up from US$2.72 in FY 2023). Revenue: US$1.72b (up 7.5% from FY 2023). Net income: US$121.1m (up 34% from FY 2023). Profit margin: 7.1% (up from 5.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.5%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year.お知らせ • Feb 05Integer Holdings Corporation (NYSE:ITGR) acquired Substantially All Assets of Precision Coating Company, Inc. for approximately $150 million.Integer Holdings Corporation (NYSE:ITGR) acquired Substantially All Assets of Precision Coating Company, Inc. for approximately $150 million on January 7, 2025. A cash consideration of $152 million will be paid by Integer Holdings Corporation, subject to adjustment for additional contingent consideration. As part of consideration, $152 million is paid towards assets of Substantially All Assets of Precision Coating Company, Inc. Integer Holdings Corporation (NYSE:ITGR) completed the acquisition of Substantially All Assets of Precision Coating Company, Inc. on January 7, 2025. Piper Sandler Companies (NYSE:PIPR) acted as financial advisor to Precision Coating Company, Inc.分析記事 • Jan 28What Is Integer Holdings Corporation's (NYSE:ITGR) Share Price Doing?Integer Holdings Corporation ( NYSE:ITGR ), is not the largest company out there, but it saw a double-digit share price...Recent Insider Transactions Derivative • Jan 24President exercised options and sold US$1.1m worth of stockOn the 21st of January, Joseph Dziedzic exercised options to acquire 8k shares at no cost and sold these for an average price of US$142 per share. This trade did not impact their existing holding. For the year to December 2018, Joseph's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Joseph's direct individual holding has increased from 222.32k shares to 224.21k. Company insiders have collectively sold US$8.1m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Jan 23Integer Holdings Corporation to Report Q4, 2024 Results on Feb 20, 2025Integer Holdings Corporation announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 20, 2025分析記事 • Jan 14Here's Why Integer Holdings (NYSE:ITGR) Has Caught The Eye Of InvestorsThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Recent Insider Transactions Derivative • Jan 07Key Executive exercised options and sold US$376k worth of stockOn the 3rd of January, John Harris exercised options to acquire 3k shares at no cost and sold these for an average price of US$134 per share. This trade did not impact their existing holding. Since March 2024, John's direct individual holding has increased from 1.47k shares to 1.52k. Company insiders have collectively sold US$7.5m more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Jan 01Integer Holdings Corporation's (NYSE:ITGR) Share Price Matching Investor OpinionInteger Holdings Corporation's ( NYSE:ITGR ) price-to-earnings (or "P/E") ratio of 38.2x might make it look like a...分析記事 • Dec 04Returns On Capital At Integer Holdings (NYSE:ITGR) Have Hit The BrakesIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Reported Earnings • Oct 24Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: EPS: US$1.08 (up from US$0.82 in 3Q 2023). Revenue: US$431.4m (up 6.6% from 3Q 2023). Net income: US$36.3m (up 33% from 3Q 2023). Profit margin: 8.4% (up from 6.7% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 4.8%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 11% per year.お知らせ • Oct 24+ 1 more updateInteger Holdings Corporation Revises Earnings Guidance for the Year 2024Integer Holdings Corporation revised earnings guidance for the year 2024. For the year, company expected sales growth of 10% to 11% with above-market organic sales growth of 7% to 8%. Sales expected to be in range of $1,707 Million to $1,727 Million. Operating income to be in range of $205 Million to $213 Million. Diluted earnings per share to be in range of $3.42 Million to $3.61 Million. Unless otherwise stated, 2024 Outlook and comparisons are presented on a continuing operations basis. Company have raised the midpoint of full year profit and EPS outlook, compared to the 2024 outlook from July, revised to exclude Electrochem.分析記事 • Oct 18Integer Holdings (NYSE:ITGR) Has A Pretty Healthy Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Oct 05Is Now An Opportune Moment To Examine Integer Holdings Corporation (NYSE:ITGR)?Integer Holdings Corporation ( NYSE:ITGR ), is not the largest company out there, but it saw a decent share price...Seeking Alpha • Oct 02Integer Holdings: More Than Re-Rated HereSummary Integer Holdings shares have surged over 25% this year due to resilient organic growth and margin expansion, leaving current valuation multiples demanding. The company, a major medical device manufacturer, has shown solid growth, with revenues doubling over the past decade to $1.6 billion in 2023. Despite a solid performance, Integer's high valuation multiples and leverage make me cautious, as recent bolt-on deals haven't significantly impacted the investment thesis. With shares trading at 25 times earnings and premium expectations, I see no reason to chase the stock at all-time highs for long-term risk-reward. Read the full article on Seeking Alphaお知らせ • Sep 27Integer Holdings Corporation to Report Q3, 2024 Results on Oct 24, 2024Integer Holdings Corporation announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Oct 24, 2024分析記事 • Sep 22Here's Why Integer Holdings (NYSE:ITGR) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...新しいナラティブ • Sep 02Expanding In High-Growth Markets With Calculated Acquisitions Boosts Revenue Potential Strong customer demand and operational improvements are poised to drive significant revenue growth and expand operating margins. 分析記事 • Aug 28Here's What To Make Of Integer Holdings' (NYSE:ITGR) Decelerating Rates Of ReturnIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • Aug 16What You Can Learn From Integer Holdings Corporation's (NYSE:ITGR) P/EWith a price-to-earnings (or "P/E") ratio of 38.4x Integer Holdings Corporation ( NYSE:ITGR ) may be sending very...Recent Insider Transactions • Aug 02Independent Director recently sold US$551k worth of stockOn the 31st of July, Jean Hobby sold around 5k shares on-market at roughly US$120 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$992k. Insiders have been net sellers, collectively disposing of US$2.9m more than they bought in the last 12 months.Recent Insider Transactions Derivative • Aug 01Key Executive notifies of intention to sell stockJohn Harris intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of July. If the sale is conducted around the recent share price of US$124, it would amount to US$421k. Since March 2024, John's direct individual holding has increased from 1.47k shares to 4.92k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Jul 28Estimating The Fair Value Of Integer Holdings Corporation (NYSE:ITGR)Key Insights The projected fair value for Integer Holdings is US$120 based on 2 Stage Free Cash Flow to Equity Current...Reported Earnings • Jul 26Second quarter 2024 earnings: EPS exceeds analyst expectationsSecond quarter 2024 results: EPS: US$0.93 (up from US$0.72 in 2Q 2023). Revenue: US$436.2m (up 9.0% from 2Q 2023). Net income: US$31.2m (up 30% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.8%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 6% per year.お知らせ • Jul 26Integer Holdings Corporation Provides Earnings Guidance for the Year 2024Integer Holdings Corporation provided earnings guidance for the year 2024. For the year, the company expects sales in the range of $1,735 million to $1,770 million, Operating income in the range of $202 million to $220 million, Net income in the range of $116 million to $130 million, Diluted earnings per share in the range of $3.26 to $3.67.収支内訳Integer Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NYSE:ITGR 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費03 Apr 261,8561422195131 Dec 251,8541032114926 Sep 251,831872025027 Jun 251,795841965128 Mar 251,746781895231 Dec 241,7171211845327 Sep 241,6721151825628 Jun 241,6371071795829 Mar 241,585971765831 Dec 231,556891716129 Sep 231,524791686230 Jun 231,469671646331 Mar 231,444671626231 Dec 221,331601575930 Sep 221,317681555901 Jul 221,280741515501 Apr 221,242831465531 Dec 211,221931425201 Oct 211,177881405002 Jul 211,107971385002 Apr 211,035681364931 Dec 201,073771374802 Oct 201,130731404903 Jul 201,198731424903 Apr 201,2721011414831 Dec 191,258911394727 Sep 191,235991384528 Jun 191,237601384529 Mar 191,237551414728 Dec 181,215471424928 Sep 181,214831435229 Jun 181,1951111425230 Mar 181,162971405029 Dec 171,136871434929 Sep 171,193401394830 Jun 171,254321424731 Mar 171,321221454930 Dec 161,076251344830 Sep 161,345-271465501 Jul 161,145-381325801 Apr 16971-281175801 Jan 16800-8985302 Oct 1565331905003 Jul 15678459049質の高い収益: ITGRは 高品質の収益 を持っています。利益率の向上: ITGRの現在の純利益率 (7.6%)は、昨年(4.5%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ITGRの収益は過去 5 年間で年間7.8%増加しました。成長の加速: ITGRの過去 1 年間の収益成長率 ( 80.9% ) は、5 年間の平均 ( 年間7.8%を上回っています。収益対業界: ITGRの過去 1 年間の収益成長率 ( 80.9% ) はMedical Equipment業界14.8%を上回りました。株主資本利益率高いROE: ITGRの 自己資本利益率 ( 8.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/22 09:53終値2026/05/22 00:00収益2026/04/03年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Integer Holdings Corporation 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Jasper HellwegArgus Research CompanyRobert WassermanBenchmark CompanyTravis SteedBofA Global Research14 その他のアナリストを表示
Reported Earnings • May 01First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: EPS: US$0.48 (up from US$0.66 loss in 1Q 2025). Revenue: US$439.6m (flat on 1Q 2025). Net income: US$16.5m (up US$39.0m from 1Q 2025). Profit margin: 3.8% (up from net loss in 1Q 2025). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 02Integer Holdings Corporation to Report Q1, 2026 Results on Apr 30, 2026Integer Holdings Corporation announced that they will report Q1, 2026 results Pre-Market on Apr 30, 2026
Reported Earnings • Feb 20Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: US$2.96 (down from US$3.60 in FY 2024). Revenue: US$1.85b (up 8.0% from FY 2024). Net income: US$102.8m (down 15% from FY 2024). Profit margin: 5.5% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.3%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 22Integer Holdings Corporation to Report Q4, 2025 Results on Feb 19, 2026Integer Holdings Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 19, 2026
分析記事 • Nov 05Some May Be Optimistic About Integer Holdings' (NYSE:ITGR) EarningsThe most recent earnings report from Integer Holdings Corporation ( NYSE:ITGR ) was disappointing for shareholders...
Reported Earnings • Oct 24Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$1.13 (up from US$1.08 in 3Q 2024). Revenue: US$467.7m (up 8.4% from 3Q 2024). Net income: US$39.7m (up 9.4% from 3Q 2024). Profit margin: 8.5% (up from 8.4% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.0%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Seeking Alpha • May 21Integer Holdings: Rare Public Asset Soon To Be SoldSummary Integer Holdings Corp. is a unique, high-quality medical device CDMO trading at a depressed ~10x EBITDA multiple after a temporary growth slowdown. A strategic review, prompted by activist involvement and heightened buyer interest, positions ITGR for a likely sale within three to four months. Precedent CDMO transactions support a fair value of $110–125/share (13–14x forward EBITDA), offering 20–40% upside with limited downside risk. ITGR’s entrenched OEM relationships, high switching costs, and diversified pipeline underpin its competitive moat and long-term growth prospects. Read the full article on Seeking Alpha
ライブニュース • May 15Integer Holdings Jumps Over 5% on Analyst Upgrade and Potential Sale ReviewInteger Holdings stock moved more than 5% higher after an Oppenheimer analyst upgraded the rating to buy. The upgrade was based on an ongoing review that could result in a potential sale of the company. The analyst highlighted Integer’s position as a contract developer and manufacturer of medical devices as a key reason it may appeal to private equity buyers. The focus on a potential sale puts extra attention on Integer’s business profile and profitability, as those factors often matter to financial buyers looking at specialized healthcare suppliers. Investors should keep in mind that interest from potential acquirers does not guarantee any transaction or specific terms, and deal speculation can add volatility to the stock.
ナラティブの更新 • May 07ITGR: Fair View Sees 2026 Product Drag Easing As Portfolio Review ProgressesInteger Holdings' analyst fair value estimate has increased from $93.25 to $95.00 as analysts factor in updated price targets from Citi, BofA, and Raymond James, along with more cautious assumptions for growth, margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the stock as recent price targets such as US$101 indicate confidence in the company’s ability to support a higher valuation over time.
お知らせ • May 03Integer Holdings Corporation Announces Earnings Guidance for the Year 2026Integer Holdings Corporation announced earnings guidance for the year 2026. For the year, the company expects as reported sales in the range of $1,805 million to $1,835 million decrease of 3% to 1% as compared to previous year, operating income in the range of $165 million to $185 million decrease of 25% to 16% as compared to previous year, net income in the range of $105 million to $125 million increase of 2% to 21% as compared to previous year, and diluted earnings per share in the range of $3.07 to $3.64 increase of 6% to 26% as compared to previous year.
Reported Earnings • May 01First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: EPS: US$0.48 (up from US$0.66 loss in 1Q 2025). Revenue: US$439.6m (flat on 1Q 2025). Net income: US$16.5m (up US$39.0m from 1Q 2025). Profit margin: 3.8% (up from net loss in 1Q 2025). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
ナラティブの更新 • Apr 20ITGR: Fair View Expects 2026 Product Drag To Fade As Pipeline BuildsAnalysts have lifted their price targets on Integer Holdings to a range of about $92 to $101, reflecting updated views on the timing of headwinds from underperforming products and the potential contribution from new products after 2026. Analyst Commentary Recent price target revisions cluster in a range of about $92 to $101, which signals that analysts see room for upside but also recognize execution questions around product transitions and growth consistency.
お知らせ • Apr 08Integer Holdings Corporation, Annual General Meeting, May 20, 2026Integer Holdings Corporation, Annual General Meeting, May 20, 2026. Location: hilton dallas/plano granite park hotel, 5805 granite parkway, plano, plano United States
お知らせ • Apr 07Integer Holdings Corporation Announces Pamela G. Bailey, Independent Chair of the Board Will Not Stand for Re-Election At 2026 AGMInteger Holdings Corporation announced Pamela G. Bailey, who currently serves as Integer’s independent Chair of the Board, will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026.
ナラティブの更新 • Apr 05ITGR: Fair View Sees 2026 Headwinds Easing As Newer Products Gain TractionAnalysts have raised Integer Holdings' implied price target range to about $92 to $101. This reflects updated views that near term product headwinds could ease by 2026, supported by contributions from newer products.
お知らせ • Apr 02Integer Holdings Corporation to Report Q1, 2026 Results on Apr 30, 2026Integer Holdings Corporation announced that they will report Q1, 2026 results Pre-Market on Apr 30, 2026
ナラティブの更新 • Mar 20ITGR: Fair View Sees 2026 Product Headwinds Easing As Recovery ProgressesAnalysts have nudged their price expectations for Integer Holdings higher, with the updated fair value moving from $92.63 to $93.25 as they factor in recent target increases and ongoing work to address product headwinds and potential future growth drivers. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price targets, now clustered in the low to low triple digits, as recognition that recent headwinds are already reflected in expectations and that current valuation assumes a measured recovery path.
お知らせ • Mar 12Integer Holdings Corporation Announces Board Changes, Effective March 12, 2026Integer Holdings Corporation has appointed two new directors to its Board of Directors: James F. Flanagan and Aaron Kapito. These appointments are effective as of March 12, 2026, and the board size has been increased to 13 members. The Cooperation Agreement also stipulates that two incumbent directors will not stand for re-election at the 2026 Annual Meeting of Stockholders. The agreement includes provisions for the appointment of the new directors to specific board committees, including the Audit Committee, the Compensation and Organization Committee, and the Technology Strategy Committee. The Cooperation Agreement includes voting commitments, standstill restrictions, and mutual non-disparagement provisions, which remain in place until the earlier of 30 days prior to the advance notice deadline for the 2027 Annual Meeting or one year from the effective date of the agreement. Mr. Flanagan is the former Chief Operating Officer of PwC from 2014 to 2021, bringing proven diversified, strategic, operational and qualified financial expertise through 39 years of increasing client and management roles. Previously, he also served as PwC’s US Financial Services Practice Leader from 2006 to 2014, and prior to that as the Transaction Services Leader from 2001 to 2006 and Transaction Services Partner from 1994 to 2001. He has served on the Board of Directors at Belami Ecommerce, a subsidiary of SkyX Platforms Corp. from 2022 to 2025, while also serving as Audit Committee Chair. Mr. Flanagan received a B.S. in Accounting from the C.W. Post School of Professional Accountancy at Long Island University. Mr. Kapito is a Partner at Politan Capital Management L.P., an investment management firm that he co-founded in 2021. Previously, Mr. Kapito served as a Senior Analyst at Lion Point Capital from 2018 to 2021, a Senior Analyst and founding member of Delonix Capital from 2016 to 2017, and an Associate Portfolio Manager for Elliott Management L.P. from 2011 to 2016. Mr. Kapito currently serves on the boards of Rocky Mountain Steel Mills, a manufacturer of high-performance steel products, and Associated Veterinary Partners, a veterinary clinic platform. Mr. Kapito received a B.S. in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School.
ナラティブの更新 • Mar 06ITGR: Fair View Balances 2026 Product Headwinds And New Launch RecoveryNarrative Update Analysts have lifted their blended price target on Integer Holdings to $92.63 from $85.57, citing updated views on future P/E, revenue growth headwinds tied to a few underperforming products and an eventual recovery supported by new product contributions. Analyst Commentary Recent research has focused on how Integer balances valuation against execution risks tied to specific product headwinds and future growth ambitions.
Recent Insider Transactions Derivative • Mar 03CEO, President & Director exercised options and sold US$1.5m worth of stockOn the 24th of February, Payman Khales exercised options to acquire 17k shares at no cost and sold these for an average price of US$87.10 per share. This trade did not impact their existing holding. For the year to December 2019, Payman's total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Payman's direct individual holding has increased from 19.74k shares to 25.47k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months.
New Risk • Feb 22New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 42% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results.
Price Target Changed • Feb 22Price target increased by 7.4% to US$91.88Up from US$85.57, the current price target is an average from 8 analysts. New target price is 8.3% above last closing price of US$84.85. Stock is down 35% over the past year. The company is forecast to post earnings per share of US$4.19 for next year compared to US$2.96 last year.
Reported Earnings • Feb 20Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: US$2.96 (down from US$3.60 in FY 2024). Revenue: US$1.85b (up 8.0% from FY 2024). Net income: US$102.8m (down 15% from FY 2024). Profit margin: 5.5% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.3%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
ナラティブの更新 • Feb 19ITGR: Fair Value Holds As FY26 Reacceleration Faces Confidence RebuildAnalysts have trimmed their price target on Integer Holdings to $86 from $88, citing expectations that it may take a few quarters before investors gain confidence in a potential reacceleration discussed for the second half of FY26. Analyst Commentary Recent research reflects a slightly more cautious stance on Integer Holdings, with the price target adjusted to $86 from $88.
お知らせ • Feb 19Integer Holdings Corporation Provides Earnings Guidance for the Year 2026Integer Holdings Corporation provided earnings guidance for the year 2026. For the year, the company expects as reported sales in the range of $1,826 million to $1,876 million, operating income in the range of $184 million to $204 million, net income in the range of $121 million to $138 million, and diluted earnings per share in the range of $3.53 to $4.01.
ナラティブの更新 • Feb 05ITGR: Fair Value Holds As 2026 Reacceleration Awaits Coatings Asset IntegrationAnalysts reduced their price target for Integer Holdings to US$86 from US$88, citing expectations that it may take a few quarters before investors are comfortable underwriting a potential re acceleration in the second half of FY26. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares, suggesting they still see support for the current valuation even with a slightly lower price target.
お知らせ • Jan 28Integer Holdings Corporation to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During Md&M West 2026Integer Holdings Corporation will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 - 5. Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company's full range of customer solutions. On prominent display will be R&D Velocity, Integer's integrated R&D ecosystem connecting design, prototyping and manufacturing to help medical device companies develop products that are manufacturable from the start, accelerating the time between design and manufacturability. The company will showcase several solutions - delivered through a network of locations globally - that are central to R&D Velocity, including: Differentiated Technology Platforms: Proven product technologies that enable, accelerate and de-risk the development of customers' next generation devices. Global Capabilities and Expertise: Specialized labs and integrated manufacturing all in one ecosystem along with dedicated engineers and global centers of excellence to accelerate every phase of development. Ease of Manufacturability: Designs optimized early to scale seamlessly, reducing rework and accelerating launch. Rapid Prototyping: Engineer-to-engineer collaboration delivering prototypes in as little as two weeks. Integer will additionally highlight a range of key product areas and innovations during MD&M West, including: Integer Medical Coatings: The company continues to expand its role as a fully integrated coating partner for medical devices, strengthening its ability to deliver end-to-end surface-modification solutions. Integer will also showcase its full coatings portfolio, including PTFE, PTFE alternatives, hydrophilic coatings, parylene, and advanced surface-modification technologies. Following the acquisitions of Precision Coating,VSi Parylene, and certain Biocoat assets last year, Integer has further strengthened its position as a fully integrated coating partner For medical devices. Cardiac Rhythm Management and Neuromodulation: Miniaturized technologies for finished IPG systems, as well as Gen 3 Li-Ion and Gen 2 CFx batteries. Cardio and Vascular: A full range of electrophysiology, structural heart, and neurovascular product solutions including complex catheters, guidewires, steerable introducers and sheaths, therapy delivery systems and implant technologies.
お知らせ • Jan 22Integer Holdings Corporation to Report Q4, 2025 Results on Feb 19, 2026Integer Holdings Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 19, 2026
ナラティブの更新 • Jan 21ITGR: Fair Value Suggests Recovery As 2026 Demand Visibility Gradually ImprovesAnalysts have modestly trimmed their blended price target for Integer Holdings to about $86, down from prior targets clustered closer to $88 and above. This reflects caution around the company's softer 2026 outlook and reduced visibility on the timing of any potential demand recovery.
ナラティブの更新 • Jan 07ITGR: Fair Value Suggests Shares Will Recover As 2026 Visibility ImprovesAnalysts have inched their fair value estimate for Integer Holdings higher to about US$85.57 from roughly US$84.29, reflecting lower assumed discount rates and a slightly higher future P/E multiple. This follows recent research updates that cut price targets and ratings but still highlight the potential for recovery once revenue visibility improves.
ナラティブの更新 • Dec 17ITGR: Shares Will Recover As 2026 Demand Visibility And Orders Gradually StabilizeThe analyst price target for Integer Holdings has been trimmed modestly, with analysts citing reduced 2026 visibility, order and demand headwinds across several newer product launches, and a longer wait for growth reacceleration as reasons for resetting expectations, even as they see the recent share price pullback as overdone. Analyst Commentary Bullish analysts acknowledge the near term reset to expectations but argue that the recent compression in Integer Holdings valuation already discounts a prolonged period of slower growth and execution risk.
お知らせ • Dec 11Saxena White P.A. Files Securities Fraud Class Action Against Integer Holdings Corporation and Certain of its ExecutivesSaxena White P.A. has filed a securities fraud class action lawsuit (the “Class Action”) in the United States District Court for the Southern District of New York against Integer Holdings Corporation (“Integer” or the “Company”) and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder on behalf of all persons or entities that purchased Integer common stock between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Saxena White is captioned West Palm Beach Firefighters’ Pension Fund v. Integer Holdings Corporation, et al., No. 25-cv-10251 (S.D.N.Y.).Based in Plano, Texas, Integer purports to be one of the medical device contract development and manufacturing organizations in the world. The Company contracts with medical device companies to manufacture cardiac rhythm management and cardio and vascular (“C&V”) medical devices. Integer’s C&V product line generates approximately 60% of the Company’s total revenue. As a part of the C&V product line, Integer manufactures electrophysiology (“EP”) devices, which diagnose and map the heart’s electrical activity to address problems such as irregular heartbeats (cardiac arrhythmias).Prior to the Class Period, EP devices underwent a technological revolution as Integer customers began to develop devices for pulse field ablation (“PFA”) procedures that use brief, high-energy electrical pulses to treat atrial fibrillation. In turn, the industry became increasingly focused on integrating EP devices and PFA platforms to effectuate a more seamless cardiac procedure. As a result, EP devices represented a significant growth driver for Integer’s C&V segment. Leading up to the Class Period, CEO Dziedzic described PFA platforms as “a tailwind” due to the Company’s “vertically integrated offering[,]” while also touting that Integer “benefit[ed] significantly from electrophysiology procedure growth.” CEO Dziedzic further explained, “We participate in the full procedure, which is one of the strengths of Integer.” The Class Action alleges that, during the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose that: (1) Integer materially overstated its competitive position within the growing EP manufacturing market; (2) despite Integer’s claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company’s C&V segment; (4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
ナラティブの更新 • Dec 03ITGR: Shares Will Recover As 2026 Demand Visibility Gradually ImprovesAnalysts have trimmed their price target on Integer Holdings slightly, to about $84.57 from roughly $84.86, as they factor in softer near term visibility and delayed confidence in a second half 2026 re acceleration, despite longer term optimism about the company’s recovery and customer relationships. Analyst Commentary Street research following Integer Holdings recent update reflects a sharply reset near term outlook, but also a degree of longer term confidence in the company’s strategic positioning and customer relationships.
ナラティブの更新 • Nov 19ITGR: Shares Will Recover As Order Headwinds Are ResolvedInteger Holdings' average analyst price target has sharply decreased, dropping from above $120 to a range of $77 to $88. Analysts cite concerns that recent order shifts, lowered guidance, and uncertainty in the 2026 outlook justify a reset in valuation expectations for the stock.
分析記事 • Nov 06What You Can Learn From Integer Holdings Corporation's (NYSE:ITGR) P/E After Its 35% Share Price CrashInteger Holdings Corporation ( NYSE:ITGR ) shareholders that were waiting for something to happen have been dealt a...
分析記事 • Nov 05Some May Be Optimistic About Integer Holdings' (NYSE:ITGR) EarningsThe most recent earnings report from Integer Holdings Corporation ( NYSE:ITGR ) was disappointing for shareholders...
お知らせ • Nov 05Integer Holdings Corporation (NYSE:ITGR) announces an Equity Buyback for $200 million worth of its shares.Integer Holdings Corporation (NYSE:ITGR) announces a share repurchase program. Under the program, the company will repurchase up to $200 million worth of its common stock. The company intends to primarily utilize cash on hand and free cash flows to fund the share repurchase program. The program has no expiration date.
ナラティブの更新 • Nov 05ITGR: Shares Will Recover As Demand Normalizes And Inventory Pressures EaseInteger Holdings’ analyst price target has been revised significantly lower, dropping from approximately $137 to $85 per share. Analysts cite headwinds from reduced revenue growth expectations and a weaker 2026 outlook following order changes to three key products.
Buy Or Sell Opportunity • Oct 30Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 41% to US$63.32. The fair value is estimated to be US$80.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 5.6% in 2 years. Earnings are forecast to grow by 106% in the next 2 years.
Reported Earnings • Oct 24Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$1.13 (up from US$1.08 in 3Q 2024). Revenue: US$467.7m (up 8.4% from 3Q 2024). Net income: US$39.7m (up 9.4% from 3Q 2024). Profit margin: 8.5% (up from 8.4% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.0%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Oct 24Price target decreased by 38% to US$86.00Down from US$139, the current price target is an average from 7 analysts. New target price is 18% above last closing price of US$72.91. Stock is down 42% over the past year. The company is forecast to post earnings per share of US$2.80 for next year compared to US$3.60 last year.
お知らせ • Oct 24+ 1 more updateInteger Holdings Corporation Announces CEO Changes, Effective October 24, 2025Integer Holdings Corporation appointed Payman Khales as Chief Executive Officer, effective October 24, 2025. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business, where he led a successful market- and customer-focused strategy, doubling sales in seven years and driving above-market growth, while further improving service levels and profitability. Most recently, as Chief Operating Officer, he oversaw both of Integer's business units and its global operations, further strengthening Integer's reputation as a strategic partner to medical device companies and OEMs worldwide. Prior to joining Integer, Mr. Khales held senior leadership roles at CECO Environmental Corp. and Ingersoll Rand Company. He holds an Executive MBA from Indiana University's Kelley School of Business and a Bachelor of Science in Mechanical Engineering from cole Polytechnique de Montréal. As previously disclosed, also effective October 24, 2025, Mr. Dziedzic will serve as a Special Advisor for the Company until March 31, 2026, to assist Mr. Khales with transition matters.
お知らせ • Oct 23+ 1 more updateInteger Holdings Corporation Provides Earnings Guidance for the Year 2026 and Year 2027Integer Holdings Corporation provided earnings guidance for the year 2026 and year 2027. For the year 2026, the company expects Reported sales to be down 2% to up 2% and Organic sales to be flat to up 4%. For the year 2027, the company expects growth 200 basis points above market.
ナラティブの更新 • Oct 22Analysts Lower Integer Holdings Price Target Amid Cautious Sector Outlook and Stable Growth ProjectionsAnalysts have lowered their price target for Integer Holdings from $137.00 to $121.00, citing market volatility concerns and a cautious outlook for new investment within the MedTech sector, even as expectations remain for healthy quarterly performance. Analyst Commentary Recent analyst notes provide a balanced view of Integer Holdings, with both optimism and caution expressed regarding the company’s outlook and sector dynamics.
お知らせ • Sep 25Integer Holdings Corporation to Report Q3, 2025 Results on Oct 23, 2025Integer Holdings Corporation announced that they will report Q3, 2025 results Pre-Market on Oct 23, 2025
分析記事 • Sep 09Is It Too Late To Consider Buying Integer Holdings Corporation (NYSE:ITGR)?While Integer Holdings Corporation ( NYSE:ITGR ) might not have the largest market cap around , it received a lot of...
分析記事 • Aug 12What You Can Learn From Integer Holdings Corporation's (NYSE:ITGR) P/EWith a price-to-earnings (or "P/E") ratio of 44.1x Integer Holdings Corporation ( NYSE:ITGR ) may be sending very...
分析記事 • Jul 22We Think Integer Holdings (NYSE:ITGR) Can Stay On Top Of Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jul 11Integer Holdings Corporation Appoints Michael Coyle to Board of DirectorsInteger Holdings Corporation announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies. Before that, he was executive vice president and group president of Medtronic’s cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career. Coyle is currently a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies Inc. and Volcano Corporation. He earned a master's degree in business administration from the Wharton School of Business, University of Pennsylvania, and a bachelor's degree from Case Western Reserve University. He additionally holds six U.S. patents related to cardiovascular medical device products and technologies.
分析記事 • Jul 08Integer Holdings Corporation (NYSE:ITGR) Shares Could Be 30% Below Their Intrinsic Value EstimateKey Insights Integer Holdings' estimated fair value is US$167 based on 2 Stage Free Cash Flow to Equity Integer...
お知らせ • Jun 30+ 5 more updatesInteger Holdings Corporation(NYSE:ITGR) dropped from Russell 3000 Value IndexInteger Holdings Corporation(NYSE:ITGR) dropped from Russell 3000 Value Index
お知らせ • Jun 26Integer Holdings Corporation to Report Q2, 2025 Results on Jul 24, 2025Integer Holdings Corporation announced that they will report Q2, 2025 results at 8:00 AM, US Eastern Standard Time on Jul 24, 2025
分析記事 • Jun 25Returns On Capital At Integer Holdings (NYSE:ITGR) Have StalledTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
Recent Insider Transactions Derivative • Jun 05Independent Director notifies of intention to sell stockDonald Spence intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of June. If the sale is conducted around the recent share price of US$120, it would amount to US$1.8m. Since March 2025, Donald has owned 18.78k shares directly. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months.
Buy Or Sell Opportunity • May 28Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 3.6% to US$119. The fair value is estimated to be US$151, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 166% in the next 2 years.
分析記事 • May 25Is Now The Time To Look At Buying Integer Holdings Corporation (NYSE:ITGR)?Integer Holdings Corporation ( NYSE:ITGR ), might not be a large cap stock, but it saw a double-digit share price rise...
分析記事 • May 02Some May Be Optimistic About Integer Holdings' (NYSE:ITGR) EarningsShareholders appeared unconcerned with Integer Holdings Corporation's ( NYSE:ITGR ) lackluster earnings report last...
Buy Or Sell Opportunity • Apr 30Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to US$126. The fair value is estimated to be US$158, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 166% in the next 2 years.
New Risk • Apr 27New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 36% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results.
Reported Earnings • Apr 25First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2025 results: US$0.66 loss per share (down from US$0.61 profit in 1Q 2024). Revenue: US$437.4m (up 5.4% from 1Q 2024). Net loss: US$22.5m (down 210% from profit in 1Q 2024). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year.
お知らせ • Apr 25Integer Holdings Corporation Provides Earnings Guidance for the Year 2025Integer Holdings Corporation provided earnings guidance for the year 2025. For the year, the company expects sales in the range of $1,846 million to $1,880 million, Operating income in the range of $242 million to $258 million, Income from continuing operations of $108 million to $120 million, Diluted earnings per share in the range of $3.00 to $3.36.
お知らせ • Apr 24+ 1 more updateInteger Holdings Corporation Announces CEO Changes, Effective October 24, 2025Integer Holdings Corporation announced that Joseph Dziedzic will retire as Chief Executive Officer, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the CEO position. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026. Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business. Under his leadership, the business established a successful market/customer-based strategy, doubling sales in seven years, accelerating market penetration, and achieving above-market growth, while improving service levels and profitability. Since becoming COO, he has overseen both of Integer’s business units, Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation, along with global operations and manufacturing strategy. Mr. Khales currently serves as COO of Integer, and previously served as President of the Cardio & Vascular product category since 2018. Prior to joining Integer, Mr. Khales served as President of the Environmental Technologies business segment for CECO Environmental Corp., a diversified global provider of engineered technologies to the environmental, energy, and fluid handling and filtration industrial segments. He also held several progressive leadership roles at Ingersoll Rand Company. Mr. Khales holds an Executive Master of Business Administration from Indiana University’s Kelley School of Business, and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal.
分析記事 • Apr 15These 4 Measures Indicate That Integer Holdings (NYSE:ITGR) Is Using Debt Reasonably WellLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Buy Or Sell Opportunity • Apr 08Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to US$107. The fair value is estimated to be US$138, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 6.7% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.
分析記事 • Apr 03Estimating The Intrinsic Value Of Integer Holdings Corporation (NYSE:ITGR)Key Insights Using the 2 Stage Free Cash Flow to Equity, Integer Holdings fair value estimate is US$143 Integer...
お知らせ • Mar 27Integer Holdings Corporation to Report Q1, 2025 Results on Apr 24, 2025Integer Holdings Corporation announced that they will report Q1, 2025 results at 8:00 AM, Eastern Standard Time on Apr 24, 2025
分析記事 • Mar 20Integer Holdings (NYSE:ITGR) Hasn't Managed To Accelerate Its ReturnsIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
お知らせ • Mar 19Integer Holdings Corporation, Annual General Meeting, May 21, 2025Integer Holdings Corporation, Annual General Meeting, May 21, 2025. Location: 5830 granite parkway, suite 1150, plano, texas 75024, United States
Recent Insider Transactions Derivative • Mar 14President exercised options and sold US$1.6m worth of stockOn the 11th of March, Joseph Dziedzic exercised options to acquire 13k shares at no cost and sold these for an average price of US$120 per share. This trade did not impact their existing holding. For the year to December 2018, Joseph's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Joseph's direct individual holding has increased from 222.32k shares to 291.78k. Company insiders have collectively sold US$9.7m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Feb 21+ 1 more updateInteger Holdings Corporation (NYSE:ITGR) signed a purchase agreement to acquire Vertical Solutions, Inc for $28 million.Integer Holdings Corporation (NYSE:ITGR) signed a purchase agreement to acquire Vertical Solutions, Inc. for $28 million on February 18, 2025. The consideration is payable $23 million in cash and $5 million in Integer common stock, subject to customary purchase price adjustments, offset by an expected $3 million NPV tax benefit. The expected completion of the transaction is by the end of February 2025.
Reported Earnings • Feb 20Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: US$3.60 (up from US$2.72 in FY 2023). Revenue: US$1.72b (up 7.5% from FY 2023). Net income: US$121.1m (up 34% from FY 2023). Profit margin: 7.1% (up from 5.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.5%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year.
お知らせ • Feb 05Integer Holdings Corporation (NYSE:ITGR) acquired Substantially All Assets of Precision Coating Company, Inc. for approximately $150 million.Integer Holdings Corporation (NYSE:ITGR) acquired Substantially All Assets of Precision Coating Company, Inc. for approximately $150 million on January 7, 2025. A cash consideration of $152 million will be paid by Integer Holdings Corporation, subject to adjustment for additional contingent consideration. As part of consideration, $152 million is paid towards assets of Substantially All Assets of Precision Coating Company, Inc. Integer Holdings Corporation (NYSE:ITGR) completed the acquisition of Substantially All Assets of Precision Coating Company, Inc. on January 7, 2025. Piper Sandler Companies (NYSE:PIPR) acted as financial advisor to Precision Coating Company, Inc.
分析記事 • Jan 28What Is Integer Holdings Corporation's (NYSE:ITGR) Share Price Doing?Integer Holdings Corporation ( NYSE:ITGR ), is not the largest company out there, but it saw a double-digit share price...
Recent Insider Transactions Derivative • Jan 24President exercised options and sold US$1.1m worth of stockOn the 21st of January, Joseph Dziedzic exercised options to acquire 8k shares at no cost and sold these for an average price of US$142 per share. This trade did not impact their existing holding. For the year to December 2018, Joseph's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Joseph's direct individual holding has increased from 222.32k shares to 224.21k. Company insiders have collectively sold US$8.1m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Jan 23Integer Holdings Corporation to Report Q4, 2024 Results on Feb 20, 2025Integer Holdings Corporation announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 20, 2025
分析記事 • Jan 14Here's Why Integer Holdings (NYSE:ITGR) Has Caught The Eye Of InvestorsThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Recent Insider Transactions Derivative • Jan 07Key Executive exercised options and sold US$376k worth of stockOn the 3rd of January, John Harris exercised options to acquire 3k shares at no cost and sold these for an average price of US$134 per share. This trade did not impact their existing holding. Since March 2024, John's direct individual holding has increased from 1.47k shares to 1.52k. Company insiders have collectively sold US$7.5m more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Jan 01Integer Holdings Corporation's (NYSE:ITGR) Share Price Matching Investor OpinionInteger Holdings Corporation's ( NYSE:ITGR ) price-to-earnings (or "P/E") ratio of 38.2x might make it look like a...
分析記事 • Dec 04Returns On Capital At Integer Holdings (NYSE:ITGR) Have Hit The BrakesIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Reported Earnings • Oct 24Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: EPS: US$1.08 (up from US$0.82 in 3Q 2023). Revenue: US$431.4m (up 6.6% from 3Q 2023). Net income: US$36.3m (up 33% from 3Q 2023). Profit margin: 8.4% (up from 6.7% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 4.8%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 11% per year.
お知らせ • Oct 24+ 1 more updateInteger Holdings Corporation Revises Earnings Guidance for the Year 2024Integer Holdings Corporation revised earnings guidance for the year 2024. For the year, company expected sales growth of 10% to 11% with above-market organic sales growth of 7% to 8%. Sales expected to be in range of $1,707 Million to $1,727 Million. Operating income to be in range of $205 Million to $213 Million. Diluted earnings per share to be in range of $3.42 Million to $3.61 Million. Unless otherwise stated, 2024 Outlook and comparisons are presented on a continuing operations basis. Company have raised the midpoint of full year profit and EPS outlook, compared to the 2024 outlook from July, revised to exclude Electrochem.
分析記事 • Oct 18Integer Holdings (NYSE:ITGR) Has A Pretty Healthy Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Oct 05Is Now An Opportune Moment To Examine Integer Holdings Corporation (NYSE:ITGR)?Integer Holdings Corporation ( NYSE:ITGR ), is not the largest company out there, but it saw a decent share price...
Seeking Alpha • Oct 02Integer Holdings: More Than Re-Rated HereSummary Integer Holdings shares have surged over 25% this year due to resilient organic growth and margin expansion, leaving current valuation multiples demanding. The company, a major medical device manufacturer, has shown solid growth, with revenues doubling over the past decade to $1.6 billion in 2023. Despite a solid performance, Integer's high valuation multiples and leverage make me cautious, as recent bolt-on deals haven't significantly impacted the investment thesis. With shares trading at 25 times earnings and premium expectations, I see no reason to chase the stock at all-time highs for long-term risk-reward. Read the full article on Seeking Alpha
お知らせ • Sep 27Integer Holdings Corporation to Report Q3, 2024 Results on Oct 24, 2024Integer Holdings Corporation announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Oct 24, 2024
分析記事 • Sep 22Here's Why Integer Holdings (NYSE:ITGR) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
新しいナラティブ • Sep 02Expanding In High-Growth Markets With Calculated Acquisitions Boosts Revenue Potential Strong customer demand and operational improvements are poised to drive significant revenue growth and expand operating margins.
分析記事 • Aug 28Here's What To Make Of Integer Holdings' (NYSE:ITGR) Decelerating Rates Of ReturnIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
分析記事 • Aug 16What You Can Learn From Integer Holdings Corporation's (NYSE:ITGR) P/EWith a price-to-earnings (or "P/E") ratio of 38.4x Integer Holdings Corporation ( NYSE:ITGR ) may be sending very...
Recent Insider Transactions • Aug 02Independent Director recently sold US$551k worth of stockOn the 31st of July, Jean Hobby sold around 5k shares on-market at roughly US$120 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$992k. Insiders have been net sellers, collectively disposing of US$2.9m more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Aug 01Key Executive notifies of intention to sell stockJohn Harris intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of July. If the sale is conducted around the recent share price of US$124, it would amount to US$421k. Since March 2024, John's direct individual holding has increased from 1.47k shares to 4.92k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Jul 28Estimating The Fair Value Of Integer Holdings Corporation (NYSE:ITGR)Key Insights The projected fair value for Integer Holdings is US$120 based on 2 Stage Free Cash Flow to Equity Current...
Reported Earnings • Jul 26Second quarter 2024 earnings: EPS exceeds analyst expectationsSecond quarter 2024 results: EPS: US$0.93 (up from US$0.72 in 2Q 2023). Revenue: US$436.2m (up 9.0% from 2Q 2023). Net income: US$31.2m (up 30% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.8%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 6% per year.
お知らせ • Jul 26Integer Holdings Corporation Provides Earnings Guidance for the Year 2024Integer Holdings Corporation provided earnings guidance for the year 2024. For the year, the company expects sales in the range of $1,735 million to $1,770 million, Operating income in the range of $202 million to $220 million, Net income in the range of $116 million to $130 million, Diluted earnings per share in the range of $3.26 to $3.67.